Compile Data Set for Download or QSAR
Report error Found 89 Enz. Inhib. hit(s) with Target = 'Nuclear receptor subfamily 2 group C member 2'
TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM665293(US20240116893, Compound 7)
Affinity DataIC50: 1.60nMAssay Description:Accordingly, the present disclosure is directed to the use of these compounds in the preparation and execution of screening assays for compounds whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM665295(US20240116893, Compound 9)
Affinity DataIC50: 1.70nMAssay Description:Accordingly, the present disclosure is directed to the use of these compounds in the preparation and execution of screening assays for compounds whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM665292(US20240116893, Compound 6)
Affinity DataIC50: 2.40nMAssay Description:Accordingly, the present disclosure is directed to the use of these compounds in the preparation and execution of screening assays for compounds whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM375312(US9908872, Compound (I-9))
Affinity DataIC50: 2.43nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM665291(US20240116893, Compound 5)
Affinity DataIC50: 2.5nMAssay Description:Accordingly, the present disclosure is directed to the use of these compounds in the preparation and execution of screening assays for compounds whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM665290(US20240116893, Compound 4)
Affinity DataIC50: 2.60nMAssay Description:Accordingly, the present disclosure is directed to the use of these compounds in the preparation and execution of screening assays for compounds whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM665289(US20240116893, Compound 3)
Affinity DataIC50: 2.80nMAssay Description:Accordingly, the present disclosure is directed to the use of these compounds in the preparation and execution of screening assays for compounds whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM665288(US20240116893, Compound 1 | US20240116893, Compoun...)
Affinity DataIC50: 3.10nMAssay Description:Accordingly, the present disclosure is directed to the use of these compounds in the preparation and execution of screening assays for compounds whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM375310(US9908872, Compound (I-8))
Affinity DataIC50: 5.33nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM375276(US9908872, Compound (I-1) | US10597387, Compound (...)
Affinity DataIC50: 7.40nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM665288(US20240116893, Compound 1 | US20240116893, Compoun...)
Affinity DataIC50: 9nMAssay Description:Accordingly, the present disclosure is directed to the use of these compounds in the preparation and execution of screening assays for compounds whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

LigandPNGBDBM50042034(CHEMBL1077979 | CHEBI:67559 | (5Z)-7-Oxozeaenol | ...)
Affinity DataIC50: 9nMAssay Description:Inhibition of Tak1/Tab1 (unknown origin) assessed as inhibition of Tak1 kinase activity preincubated for 30 mins followed by addition of MBP protein ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/23/2022
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM50379186(CEP-11981 | CHEMBL2010872)
Affinity DataIC50: 14nMAssay Description:Inhibition of human TAK1 using ATP as substrateMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2013
Entry Details Article
PubMed
TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM375281(US9908872, Compound (I-4) | US10597387, Compound (...)
Affinity DataIC50: 22.8nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM375307(US9908872, Compound (I-6) | US10597387, Compound (...)
Affinity DataIC50: 29.9nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

LigandPNGBDBM50129131(CHEBI:83275 | Hypothemycin | US10434085, Compound ...)
Affinity DataIC50: 30nMAssay Description:Inhibition of recombinant human N-terminal GST-tagged TAK1 (1 to 303 residues)/TAB1 (437 to end residues) expressed in baculovirus infected Sf9 insec...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM665296(US20240116893, Compound 10)
Affinity DataIC50: 32nMAssay Description:Accordingly, the present disclosure is directed to the use of these compounds in the preparation and execution of screening assays for compounds whic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM439303(US10633348, Compound (A-17))
Affinity DataIC50: 45nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM439318(US10633348, Compound (A-14))
Affinity DataIC50: 53.8nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM375308(US9908872, Compound (I-7) | US10597387, Compound (...)
Affinity DataIC50: 56.5nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM50086441(CHEMBL3426225 | US10266537, Compound 3)
Affinity DataIC50: 61nMAssay Description:Inhibition of human TAK1More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/6/2016
Entry Details Article
PubMed
TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM375280(US9908872, Compound (I-3) | US10597387, Compound (...)
Affinity DataIC50: 62.2nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM439308(US10633348, Compound (A-6))
Affinity DataIC50: 63.5nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM439309(US10633348, Compound (A-7))
Affinity DataIC50: 71.7nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM439316(US10633348, Compound (A-12))
Affinity DataIC50: 76.2nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM439305(US10633348, Compound (A-3))
Affinity DataIC50: 92nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM439304(US10633348, Compound (A-2))
Affinity DataIC50: 100nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM439307(US10633348, Compound (A-5))
Affinity DataIC50: 100nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM375299(US9908872, Compound (I-5) | US10597387, Compound (...)
Affinity DataIC50: 117nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM50604141(CHEMBL5188433)
Affinity DataIC50: 120nMAssay Description:Inhibition of TAK (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM50584720(CHEMBL5088153)
Affinity DataIC50: 126nMAssay Description:Inhibition of human TAK1 in presence of ATP by radiometric assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2023
Entry Details Article
PubMed
TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM439319(US10633348, Compound (A-15))
Affinity DataIC50: 136nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
Go to US Patent

LigandPNGBDBM50604138(CHEMBL5184381)
Affinity DataIC50: 180nMAssay Description:Inhibition of TAK/TAB (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM50604140(CHEMBL5185000)
Affinity DataIC50: 260nMAssay Description:Inhibition of TAK (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM438001(US10633348, Compound (A-8) | US10633348, Compound ...)
Affinity DataIC50: 364nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
Go to US Patent

LigandPNGBDBM50594358(CHEMBL5204235)
Affinity DataIC50: 380nMAssay Description:Inhibition of recombinant human N-terminal GST-tagged TAK1 (1 to 303 residues)/TAB1 (437 to end residues) expressed in baculovirus infected Sf9 insec...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM439317(US10633348, Compound (A-13))
Affinity DataIC50: 400nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
Go to US Patent

LigandPNGBDBM50594353(CHEMBL5174288)
Affinity DataIC50: 430nMAssay Description:Inhibition of recombinant human N-terminal GST-tagged TAK1 (1 to 303 residues)/TAB1 (437 to end residues) expressed in baculovirus infected Sf9 insec...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
LigandPNGBDBM50594354(CHEMBL5186931)
Affinity DataIC50: 450nMAssay Description:Inhibition of recombinant human N-terminal GST-tagged TAK1 (1 to 303 residues)/TAB1 (437 to end residues) expressed in baculovirus infected Sf9 insec...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM438001(US10633348, Compound (A-8) | US10633348, Compound ...)
Affinity DataIC50: 487nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
Go to US Patent

LigandPNGBDBM50594367(CHEMBL5207996)
Affinity DataIC50: 500nMAssay Description:Inhibition of recombinant human N-terminal GST-tagged TAK1 (1 to 303 residues)/TAB1 (437 to end residues) expressed in baculovirus infected Sf9 insec...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
LigandPNGBDBM50574560(CHEMBL4848326)
Affinity DataIC50: 580nMAssay Description:Inhibition of Tak1/Tab1 (unknown origin) assessed as inhibition of Tak1 kinase activity preincubated for 30 mins followed by addition of MBP protein ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/23/2022
Entry Details Article
PubMed
TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM439306(US10633348, Compound (A-4))
Affinity DataIC50: 591nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
Go to US Patent

LigandPNGBDBM50594360(CHEMBL5173905)
Affinity DataIC50: 630nMAssay Description:Inhibition of recombinant human N-terminal GST-tagged TAK1 (1 to 303 residues)/TAB1 (437 to end residues) expressed in baculovirus infected Sf9 insec...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
LigandPNGBDBM50594364(CHEMBL5185893)
Affinity DataIC50: 700nMAssay Description:Inhibition of recombinant human N-terminal GST-tagged TAK1 (1 to 303 residues)/TAB1 (437 to end residues) expressed in baculovirus infected Sf9 insec...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
TargetNuclear receptor subfamily 2 group C member 2(Human)
Duke University

US Patent
LigandPNGBDBM400813(QL-X-138 | US10000483, Compound II-6)
Affinity DataIC50: 717nMAssay Description:DiscoverX binding assays were performed according to published methods (Fabian et al., Nat. Biotechnol. 23, 329-36 (2005); Davis et al., Nat. Biotech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/11/2020
Entry Details
Go to US Patent

LigandPNGBDBM50594356(CHEMBL5179846)
Affinity DataIC50: 720nMAssay Description:Inhibition of recombinant human N-terminal GST-tagged TAK1 (1 to 303 residues)/TAB1 (437 to end residues) expressed in baculovirus infected Sf9 insec...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
LigandPNGBDBM50594365(CHEMBL5186989)
Affinity DataIC50: 820nMAssay Description:Inhibition of recombinant human N-terminal GST-tagged TAK1 (1 to 303 residues)/TAB1 (437 to end residues) expressed in baculovirus infected Sf9 insec...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
LigandPNGBDBM50594361(CHEMBL5174742)
Affinity DataIC50: 820nMAssay Description:Inhibition of recombinant human N-terminal GST-tagged TAK1 (1 to 303 residues)/TAB1 (437 to end residues) expressed in baculovirus infected Sf9 insec...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
LigandPNGBDBM50594371(CHEMBL5190572)
Affinity DataIC50: 1.00E+3nMAssay Description:Inhibition of recombinant human N-terminal GST-tagged TAK1 (1 to 303 residues)/TAB1 (437 to end residues) expressed in baculovirus infected Sf9 insec...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
Displayed 1 to 50 (of 89 total ) | Next | Last >>
Jump to: